Moderna reports first positive Phase 3 for mRNA neoantigen therapy in melanoma
Today marks an important milestone for @moderna_tx , for the field of mRNA, and for the many people working to bring new possibilities to patients.
This morning, Moderna and Merck announced positive Phase 3 results for adjuvant treatment with intismeran autogene, an
This morning, Moderna and Merck announced positive Phase 3 results for adjuvant treatment with intismeran autogene, an
Summary
Moderna and Merck have announced encouraging results from their Phase 3 trial of an mRNA-based treatment for melanoma, potentially paving the way for innovative cancer therapies. This breakthrough could significantly impact how melanoma is treated in the future.
Comments (290 of ) ⌛